# Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

> **NCT01072175** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 430 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK2118436
- **DRUG:** GSK1120212

## Key facts

- **NCT ID:** NCT01072175
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-26
- **Primary completion:** 2012-05-31
- **Final completion:** 2018-02-27
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01072175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01072175, "Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01072175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*